Investment Philosophy

Platform Technology with Strong Data Moat: We firmly believe in the transformative power of platform technologies, especially when paired with a unique and highly diverse datasets, to unlock groundbreaking insights and drive exponential impact.

Interdisciplinary Teams: Healthcare is evolving from chance-based discovery to computation-driven engineering. We are excited to partner with interdisciplinary teams that combine expertise in software and biology, seamlessly merging data science with biological insights.

Focusing on New Business Models: The future of healthcare is being reshaped by innovative business models that integrate AI and software with biotechnology and bioengineering. We are passionate about working with pioneering approaches, leveraging the power of AI to build scalable solutions, optimize workflows, and deliver precision, data-driven healthcare at scale.


Companies

  • Arsenal Bio Logo

    Programmable cell therapy company developing CAR-T therapies for solid tumors.


    Develops and implements of synthetic biology tools, high throughput screening, automation, AI to genetically reprogram patient’s own T cells to eradicate solid tumors- CRISPR-based approach integrates large payloads into a single site in the genome with reprograming instruction to minimizes safety risks and maximize payload size. Introduction of genetic circuit as a switching mechanism to activate CAR-T only in the site of the tumor. Data analytics and discovery engine enables building cell models and identificartion of new drug candidateds.

    CEO

    Ken Drazan

    Sector

    Stages

    Geography

    Headquarters

    San Francisco, CA

    Investors

    Kleiner Perkins, Westlake Village Biopartners, Softbank, BMS, NVentures, Regeneron, T Rowe, ARCH

  • Bioptimus Logo

    Creating the AI foundation model for Biology


    Bioptimus is creating the reference AI foundation model for biology. For the first time in history, we are connecting every scale and modality of biology to transform biological discovery and accelerate breakthroughs in biomedicine.

    CEO

    Jean-Philippe Vert

    Stages

    Geography

    Headquarters

    Paris, France

    Investors

    Cathay Innovation, Sofinnova Partners, Bpifrance, Andera Partners, Boom Capital, Pomifer Capital, Sunrise, Emmanuel Cassimatis, Thomas Wolf.

  • Cure51 Logo

    World’s first global and highly diversified clinical and molecular database of cancer survivors established thorugh a collaborative global network.


    Cure51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors. The company has been co-created with leading oncology centres and already identified more than 1500+ survivors on all continents. Cure51 has developed its own data collection and discovery platform as well as a Central Lab to proceed to a multiomic sequencing of the survivors’ samples. Cure51 aims to identify robust therapeutic targets using state of the art technologies, validated by its scientific community, in order to develop novel drugs to cure Cancer starting with 3 cancer indications.

    CEO

    Nicolas Wolikow

    Sector

    Stages

    Geography

    Headquarters

    Paris, France

    Investors

    Sofinnova, Life Extension Ventures, Xavier Niel, Olivier Pomel

  • Huma Logo

    Digital health platform using real-time health data to improve clinical care and research.


    Digital health platform enabling ‘Hospital at Home’ remotely collect patient-generated data, greater access to care outside of a conventional setting, improving efficiency and empowering patients to better manage their own health Companion App (SaMD) secure, scalable and fully compliant platform accelerates time to market for pharma and medtech customers’ regulated digital health products Digital Clinical Trial (DCT) easy-to-build and digital-first clinical trial platform that deploys trial at speed, achieve higher accuracy with continuous data collection and near real-time reporting.

    CEO

    Dan Vahdat

    Stages

    Geography

    Headquarters

    London

    Investors

    Leaps by Bayer, AstraZeneca, Samsung NEXT, Sony Innovation Fund

  • IPeace Logo

    Fully-automated mass production of induced Pluripotent Stem Cells (iPSC) for clinical research.


    Develops technology that uses biotechnology approaches to simplify the process of generating iPSCs and automates the preparation process using advanced robotics and fluidics technology. Their proprietary manufacturing platform enables fully-automated mass production of discrete iPSCs. Provides research-grade and clinical grade iPSCs for biotech companies in regenerative medicine iPSC banking service for consumers (B2C).

    CEO

    Koji Tanabe, Ph.D.

    Sector

    Stages

    Geography

    Headquarters

    San Francisco, CA

    Investors

    SBI

  • Proscia Logo

    Digital pathology solution to increase efficiency in cancer research and clinical applications.


    Concentriq Digital Pathology Platform connects image data and computational applications to aid research and diagnostic workflows and increase collaboration across instiitutions. For Biopharma: system of record for all pathology needs across discovery, preclinical and clinical R&D, and translational medicine; accelerating discovery and development while collaborating and integrating external company offerings and technologies For CROs: deliver the efficiency and quality required to tackle the highest volume tissue analysis requests For Diagnostics: help labs overcome diagnostics challenge by allowing pathologists to easily and seamlessly collaborate with peers.

    CEO

    David West

    Sector

    Stages

    Geography

    Headquarters

    Pennsylvania, USA

    Investors

    Scale Venture Partners, Siemens Healthineers, Highline Capital Management, Triangle Peak Partners, Alpha Intelligence Capital, Flybridge Capital Partners, Emerald Development

  • Relation Therapeutics Logo

    Drug discovery platform combining state-of-the-art AI models with Lab-in-the-Loop.


    Relation Therapeutics combines state-of-the-art ActiveGraph AI models with Lab-in-the-Loop to seamlessly integrate single-cell analysis and genomics to build rich maps of disease biology for drug discovery.

    CEO

    David Roblin

    Stages

    Geography

    Headquarters

    London, UK

    Investors

    Khosla Ventures, NVentures, Magnetic Ventures, Deerfield, ARK Invest, DCVC

  • Scipher Medicine Logo

    Precision immunology company matching patients with their most effective therapy for autoimmune diseases.


    Data and analytics platform at the intersection of diagnostics and drug discovery, combining interactome and network biology with proprietary patient transcriptomics data to discover unique molecular disease signatures in autoimmune disease patients.

    CEO

    Reginald Seeto

    Sector

    Stages

    Geography

    Headquarters

    Waltham, USA

    Investors

    Khosla Ventures, Northpond, aMoon, Cobal Ventures, Echo Ventures

  • SOPHiA Genetics

    Data analytics solution to support healthcare professionals by maximizing power of data-driven precision medicine.


    Decentralized, multimodal data analytics platform driven by AI deployed through a global network of healthcare providers . Platform with comprehensive portfolio of applications comprising genomics, radiology and clinical data with broad indication coverage (cancer, cardiology, nephropathies and hereditary diseases). Collaborative business model that is built to lead the data race: over 750+ health institutions globally connected. Easily integrated in existing workflow and in-house analytics ensure institutional data ownership. Seamless, automated data transfer between technologies, EHR, LIMS, database and interpretation tools for streamlined workflow.

    CEO

    Jurgi Camblong

    Sector

    Stages

    Geography

    Headquarters

    Massachusetts

    Investors

    Balderton, aMoon, Swisscom Ventures

Dan Vahdat

Wolfgang and the Hitachi team have truly felt like an extension of our own team. Whenever we reach out for help, they are always there—deeply committed to Huma’s mission and success, and unwaveringly consistent through all our ups and downs.


Dan Vahdat

Huma Logo

Sector Team

Perspectives